1. van Os, J. & Kapur, S. Schizophrenia. Lancet 374, 635–645 (2009).
2. Belmaker, R. H. Bipolar disorder. N. Engl. J. Med. 351, 476–486 (2004).
3. Miyamoto, S. et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79–104 (2005).
4. Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 25, 238–246 (1989).
5. Broekkamp, C. L. et al. Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneimittelforschung 40, 544–549 (1990).